UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 128

Sortiert nach

S1169 The Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat Containing X1 Agonist NX-13 Demonstrates Rapid Symptomatic and Biomarkers Improvement in Ulcerative Colitis: Results in a Phase 1b Study

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S895-S896

2023

Link zum Volltext

Verfügbarkeit prüfen

S1206 Rapid Symptomatic Relief Is Correlated with Early Endoscopic Response to the Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat Containing X1 (Nlrx1) Agonist Nx-13 in Ulcerative Colitis in a Phase 1b Study

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S919-S920

2023

Link zum Volltext

Verfügbarkeit prüfen

S1110 Target Engagement and Pharmacodynamic Molecular Mechanism Evaluation in a Phase 1b Study of the Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat Containing X1 (NLRX1) Agonist NX-13 in Ulcerative Colitis

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S845-S846

2023

Link zum Volltext

Verfügbarkeit prüfen

S928 Effect of Etrasimod on Circulating Lymphocytes in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e673-e673

2022

Link zum Volltext

Verfügbarkeit prüfen

S455 Efficacy and Safety of the Selective Sphingosine 1-Phosphate Receptor Modulator, Etrasimod, in Adult Patients With Eosinophilic Esophagitis: Primary Results From the Phase 2 VOYAGE Study

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S330-S331

2023

Link zum Volltext

Verfügbarkeit prüfen

S734 Etrasimod 2mg Once Daily as Treatment for Patients With Moderately to Severely Active Ulcerative Colitis: Topline and Subgroup Analysis From ELEVATE UC 52 and ELEVATE UC 12

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e516-e517

2022

Link zum Volltext

Verfügbarkeit prüfen

Assessing Cranial Nerves in Physical Therapy Practice: Findings from a Cross-Sectional Survey and Implication for Clinical Practice

Healthcare (Basel), 2021-09, Vol.9 (10), p.1262

2021

Link zum Volltext

Verfügbarkeit prüfen

Hip bone marrow edema presenting as low back pain: a case report

Physiotherapy theory and practice, 2020-01, Vol.36 (1), p.249-257

2020

Link zum Volltext

Verfügbarkeit prüfen

Physiotherapy Screening for Referral of a Patient with Patent Foramen Ovale Presenting with Neck Pain as Primary Complaint: A Case Report

Healthcare (Basel), 2023-04, Vol.11 (8), p.1165

2023

Link zum Volltext

Verfügbarkeit prüfen

Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study

Intestinal research, 2020, 18(1), , pp.45-55

2020

Link zum Volltext

Verfügbarkeit prüfen

402 THE EFFECT OF NLRX1 ACTIVATION ON EOSINOPHILS IN ULCERATIVE COLITIS AND INFLAMMATION: TRANSLATIONAL LEARNINGS ACROSS DISEASES AND FROM MOUSE TO HUMAN

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-93-S-93

2024

Link zum Volltext

Verfügbarkeit prüfen

Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1

Journal of Crohn's and colitis, 2018-08, Vol.12 (suppl_2), p.S669-S677

2018

Link zum Volltext

Verfügbarkeit prüfen

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

The Lancet (British edition), 2023-04, Vol.401 (10383), p.1159-1171

2023

Link zum Volltext

Verfügbarkeit prüfen

Neoplastic malignant cord compression mimicking low back pain: A case report

Physiotherapy research international : the journal for researchers and clinicians in physical therapy, 2023-01, Vol.28 (1), p.e1971-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Tu1737 ROLE OF NLRX1 AGONIST NX-13 IN REDUCING VISCERAL HYPERSENSITIVITY IN PRECLINICAL GASTROINTESTINAL INFLAMMATION

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-1400-S-1400

2024

Link zum Volltext

Verfügbarkeit prüfen

A pharmacokinetic comparison of anrukinzumab, an anti‐ IL‐13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients

British journal of clinical pharmacology, 2015-07, Vol.80 (1), p.101-109

2015

Link zum Volltext

Verfügbarkeit prüfen

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II)

Gut, 2019-01, Vol.68 (1), p.40

2019

Link zum Volltext

Verfügbarkeit prüfen

S0780 Patient-Reported Disease Activity in a Large Sample of Ulcerative Colitis (UC) Patients Using Social Media-Delivered Questionnaires

The American journal of gastroenterology, 2020-10, Vol.115 (1), p.S398-S398

2020

Link zum Volltext

Verfügbarkeit prüfen

Tu1718 A PHASE 1B STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS AND CLINICAL EFFICACY OF THE NUCLEOTIDEBINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS

Gastroenterology (New York, N.Y. 1943), 2023-05, Vol.164 (6), p.S-1092-S-1092

2023

Link zum Volltext

Verfügbarkeit prüfen

Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study

Gut, 2015-06, Vol.64 (6), p.894-900

2015

Link zum Volltext

Verfügbarkeit prüfen

635 EFFICACY AND SAFETY OF THE SELECTIVE SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, ETRASIMOD, IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS OVER 52 WEEKS IN THE PHASE 2 VOYAGE STUDY

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-146-S-147

2024

Link zum Volltext

Verfügbarkeit prüfen

215 Efficacy and Safety of Upadacitinib as an Induction Therapy for Patients With Moderately-to-Severely Active Ulcerative Colitis: Combined Results From 382 Subjects in the Phase 2b Study U-ACHIEVE

The American journal of gastroenterology, 2019-10, Vol.114 (1), p.S131-S131

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo‐controlled trial (CAPTIVATE)

Neurogastroenterology and motility, 2023-05, Vol.35 (5), p.e14539-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 128

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(120)
Mit Volltextzugriff
(96)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(51)
Life Sciences & Biomedicine
(41)
Humans
(32)
Female
(19)
Male
(16)
Adult
(14)
Middle Aged
(14)
Gastroenterology & Hepatology
(13)
Inflammatory Bowel Disease
(11)
Aged
(10)
Double-Blind Method
(10)
Treatment Outcome
(10)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(9)
Patients
(8)
Technology
(8)
Colitis, Ulcerative - Drug Therapy
(7)
Endoscopy
(7)
Crohn Disease - Drug Therapy
(6)
Gastroenterology
(6)
Gastroenterology And Hepatology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

S1169 The Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat Containing X1 Agonist NX-13 Demonstrates Rapid Symptomatic and Biomarkers Improvement in Ulcerative Colitis: Results in a Phase 1b Study

S1206 Rapid Symptomatic Relief Is Correlated with Early Endoscopic Response to the Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat Containing X1 (Nlrx1) Agonist Nx-13 in Ulcerative Colitis in a Phase 1b Study

S1110 Target Engagement and Pharmacodynamic Molecular Mechanism Evaluation in a Phase 1b Study of the Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat Containing X1 (NLRX1) Agonist NX-13 in Ulcerative Colitis

S928 Effect of Etrasimod on Circulating Lymphocytes in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials

S455 Efficacy and Safety of the Selective Sphingosine 1-Phosphate Receptor Modulator, Etrasimod, in Adult Patients With Eosinophilic Esophagitis: Primary Results From the Phase 2 VOYAGE Study

S734 Etrasimod 2mg Once Daily as Treatment for Patients With Moderately to Severely Active Ulcerative Colitis: Topline and Subgroup Analysis From ELEVATE UC 52 and ELEVATE UC 12

Assessing Cranial Nerves in Physical Therapy Practice: Findings from a Cross-Sectional Survey and Implication for Clinical Practice

Hip bone marrow edema presenting as low back pain: a case report

Physiotherapy Screening for Referral of a Patient with Patent Foramen Ovale Presenting with Neck Pain as Primary Complaint: A Case Report

Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study

402 THE EFFECT OF NLRX1 ACTIVATION ON EOSINOPHILS IN ULCERATIVE COLITIS AND INFLAMMATION: TRANSLATIONAL LEARNINGS ACROSS DISEASES AND FROM MOUSE TO HUMAN

Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

Neoplastic malignant cord compression mimicking low back pain: A case report

Tu1737 ROLE OF NLRX1 AGONIST NX-13 IN REDUCING VISCERAL HYPERSENSITIVITY IN PRECLINICAL GASTROINTESTINAL INFLAMMATION

A pharmacokinetic comparison of anrukinzumab, an anti‐ IL‐13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II)

S0780 Patient-Reported Disease Activity in a Large Sample of Ulcerative Colitis (UC) Patients Using Social Media-Delivered Questionnaires

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study

Tu1718 A PHASE 1B STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS AND CLINICAL EFFICACY OF THE NUCLEOTIDEBINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS

Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study

635 EFFICACY AND SAFETY OF THE SELECTIVE SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, ETRASIMOD, IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS OVER 52 WEEKS IN THE PHASE 2 VOYAGE STUDY

215 Efficacy and Safety of Upadacitinib as an Induction Therapy for Patients With Moderately-to-Severely Active Ulcerative Colitis: Combined Results From 382 Subjects in the Phase 2b Study U-ACHIEVE

Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo‐controlled trial (CAPTIVATE)

Suchergebnisse filtern